Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels

Raimo Tuuminen,1 Sirpa Loukovaara2 1Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland; 2Unit of Vitreoretinal Surgery, Dept of Ophthalmology, Helsinki University Hospital, University of Helsinki, Helsinki, FinlandBackground: In eyes with idiopathic epiretinal membrane (iERM),...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Tuuminen R, Loukovaara S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
EPO
Acceso en línea:https://doaj.org/article/a582998d4220427abc009619eb1f62a6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:a582998d4220427abc009619eb1f62a6
record_format dspace
spelling oai:doaj.org-article:a582998d4220427abc009619eb1f62a62021-12-02T00:21:57ZStatin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels1177-5483https://doaj.org/article/a582998d4220427abc009619eb1f62a62016-05-01T00:00:00Zhttps://www.dovepress.com/statin-medication-in-patients-with-epiretinal-membrane-is-associated-w-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Raimo Tuuminen,1 Sirpa Loukovaara2 1Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland; 2Unit of Vitreoretinal Surgery, Dept of Ophthalmology, Helsinki University Hospital, University of Helsinki, Helsinki, FinlandBackground: In eyes with idiopathic epiretinal membrane (iERM), the intravitreal growth factor and cytokine levels may associate with postvitrectomy outcomes. Here, we have analyzed the perioperative intravitreal protein levels of potent vasoactive, proinflammatory, and extracellular matrix-remodeling factors in iERM eyes and evaluated the postvitrectomy outcomes.Methods: This was an institutional, observational study. Eyes operated on for iERM (n=26) were analyzed according to the use of statin medication. Vitreous samples were subjected to protein measurements of angiopoietin-1 and -2, erythropoietin, transforming growth factor-β1, and vascular endothelial growth factor by enzyme-linked immunosorbent assay, and of matrix metalloproteinase-2 and -9 by gelatin zymography. One-month visual outcomes and 1-year revitrectomy rates were recorded.Results: In iERM eyes of patients taking statins, intravitreal levels of erythropoietin (mean ± standard deviation, 10.8±4.9 vs 82.9±119.5 mIU/mg, P=0.003), transforming growth factor-β1 (2.3±4.7 vs 15.8±16.3 pg/mg, P=0.035), and vascular endothelial growth factor (5.5±9.9 vs 236.6±491.6 pg/mg, P=0.006) were lower than in nonstatin-treated patients. At 1-month, visual gain did not significantly differ between iERM eyes of patients with statins and those without (improvement 0.27±0.20 vs 0.16±0.38 logarithm of the minimum angle of resolution units, P=0.118).Conclusion: Systemic statin therapy might have a favorable effect on intravitreal factors involved in vascular permeability, inflammation, and fibroproliferation in aging human iERM eyes.Keywords: epiretinal membrane, erythropoietin, HMG-CoA reductase inhibitors, transforming growth factor-beta, vascular endothelial growth factor, vitrectomyTuuminen RLoukovaara SDove Medical Pressarticleepiretinal membraneEPOHMG-CoA reductase inhibitorsTGF-betaVEGFvitrectomyOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2016, Iss Issue 1, Pp 921-928 (2016)
institution DOAJ
collection DOAJ
language EN
topic epiretinal membrane
EPO
HMG-CoA reductase inhibitors
TGF-beta
VEGF
vitrectomy
Ophthalmology
RE1-994
spellingShingle epiretinal membrane
EPO
HMG-CoA reductase inhibitors
TGF-beta
VEGF
vitrectomy
Ophthalmology
RE1-994
Tuuminen R
Loukovaara S
Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels
description Raimo Tuuminen,1 Sirpa Loukovaara2 1Department of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland; 2Unit of Vitreoretinal Surgery, Dept of Ophthalmology, Helsinki University Hospital, University of Helsinki, Helsinki, FinlandBackground: In eyes with idiopathic epiretinal membrane (iERM), the intravitreal growth factor and cytokine levels may associate with postvitrectomy outcomes. Here, we have analyzed the perioperative intravitreal protein levels of potent vasoactive, proinflammatory, and extracellular matrix-remodeling factors in iERM eyes and evaluated the postvitrectomy outcomes.Methods: This was an institutional, observational study. Eyes operated on for iERM (n=26) were analyzed according to the use of statin medication. Vitreous samples were subjected to protein measurements of angiopoietin-1 and -2, erythropoietin, transforming growth factor-β1, and vascular endothelial growth factor by enzyme-linked immunosorbent assay, and of matrix metalloproteinase-2 and -9 by gelatin zymography. One-month visual outcomes and 1-year revitrectomy rates were recorded.Results: In iERM eyes of patients taking statins, intravitreal levels of erythropoietin (mean ± standard deviation, 10.8±4.9 vs 82.9±119.5 mIU/mg, P=0.003), transforming growth factor-β1 (2.3±4.7 vs 15.8±16.3 pg/mg, P=0.035), and vascular endothelial growth factor (5.5±9.9 vs 236.6±491.6 pg/mg, P=0.006) were lower than in nonstatin-treated patients. At 1-month, visual gain did not significantly differ between iERM eyes of patients with statins and those without (improvement 0.27±0.20 vs 0.16±0.38 logarithm of the minimum angle of resolution units, P=0.118).Conclusion: Systemic statin therapy might have a favorable effect on intravitreal factors involved in vascular permeability, inflammation, and fibroproliferation in aging human iERM eyes.Keywords: epiretinal membrane, erythropoietin, HMG-CoA reductase inhibitors, transforming growth factor-beta, vascular endothelial growth factor, vitrectomy
format article
author Tuuminen R
Loukovaara S
author_facet Tuuminen R
Loukovaara S
author_sort Tuuminen R
title Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels
title_short Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels
title_full Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels
title_fullStr Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels
title_full_unstemmed Statin medication in patients with epiretinal membrane is associated with low intravitreal EPO, TGF-beta-1, and VEGF levels
title_sort statin medication in patients with epiretinal membrane is associated with low intravitreal epo, tgf-beta-1, and vegf levels
publisher Dove Medical Press
publishDate 2016
url https://doaj.org/article/a582998d4220427abc009619eb1f62a6
work_keys_str_mv AT tuuminenr statinmedicationinpatientswithepiretinalmembraneisassociatedwithlowintravitrealepotgfbeta1andvegflevels
AT loukovaaras statinmedicationinpatientswithepiretinalmembraneisassociatedwithlowintravitrealepotgfbeta1andvegflevels
_version_ 1718403820542754816